Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension
NCT ID: NCT04910100
Last Updated: 2024-04-17
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
226 participants
Study Classification
INTERVENTIONAL
Study Start Date
2021-04-15
Study Completion Date
2022-04-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to evaluate the safety (in the eye and throughout the body) and effectiveness of nebivolol (0.5 and 1 percent) and timolol (0.5 percent) eye drop suspensions. These eye drops will be compared to timolol 0.5 percent eye drop solution in participants with open angle glaucoma (the most common type of glaucoma) or high eye pressure (ocular hypertension).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension
NCT01068964
Open-angle Glaucoma
Ocular Hypertension
COMPLETED
NA
Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
NCT01215786
Glaucoma, Open-Angle
Ocular Hypertension
COMPLETED
PHASE1
Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients
NCT00651612
Glaucoma
Ocular Hypertension
COMPLETED
PHASE3
A Study of Glaucoma or Ocular Hypertension in Patients Within the United States
NCT00800267
Ocular Hypertension
Glaucoma
COMPLETED
PHASE3
Evaluation of Nanodropper-mediated Microdrops vs. Standard Drops of 0.5% Timolol Maleate in Glaucoma Patients
NCT05181046
Glaucoma
Glaucoma, Open-Angle
Glaucoma, Primary Open Angle
+2 more
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will enroll 240 participants (60 in each treatment arm) who will be treated for 84 days (12 weeks). Participants will have OAG (open angle glaucoma) or OHT (ocular hypertension) in both eyes (OAG in one eye and OHT in the follow eye is acceptable) that requires therapy and elevated IOP (intraocular pressure) adequately controlled on no more than 2 ocular hypertensive medications. Participants with OHT on no ocular hypotensive medications are acceptable. After being informed about the study and potential risks, participants giving written informed consent will undergo an washout period, if required, from previous glaucoma medications (28 days for prostaglandin analogs, rho-associated protein kinase inhibitors, or beta blockers; 14 days for adrenergic agonists; and 5 days for muscarinic agonists or carbonic anhydrase inhibitors). Eligible participants must have unmedicated IOP measurements at Visit 3/Baseline ≥ 22 and ≤ 34 mm Hg at 8:00 AM and ≥ 18 and ≤ 34 mm Hg at 10:00 AM and 4:00 PM (each qualifying eye must fall within the required IOP range at all 3 time points and must be at least 22 mm Hg at each consecutive measurement at the 8:00 AM time point). Both eyes will be treated twice daily. Study visits will comprise Visit 1/Screening/Day -35 to -1, Visit 2/Washout Safety Check/Day -14 ± 3 (performed for participants undergoing 28-day washout periods at the Investigator's discretion), Visit 3/Qualification/Baseline/Day 1, Visit 4/Day 15 ± 3, Visit 5/Day 42 ± 3, and Visit 6/Day 84 ± 3. At Visits 4, 5, and 6, participants will be evaluated at 8:00 AM, at 2 hours after study medication dosing at the clinical site (approximately 10:00 AM), and at 4:00 PM (each ± 30 minutes). All ophthalmic assessments will be performed bilaterally.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Open-Angle Glaucoma
Ocular Hypertension
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Eligible participants will be randomized in a 1:1:1:1 ratio to 4 treatment arms: nebivolol 0.5% ophthalmic suspension; nebivolol 1.0% ophthalmic suspension; timolol 0.5% ophthalmic suspension; and timolol 0.5% ophthalmic solution.
Primary Study Purpose
TREATMENT
Blinding Strategy
TRIPLE
Caregivers
Investigators
Outcome Assessors
The study is observer masked. The study medication will be provided in foil pouches contained in identical-appearing boxes. An unmasked staff member not involved in performing study endpoint-related procedures (i.e., IOP measurement) will be responsible for providing dosing instructions, dispensing study medication, and conducting study medication accountability and dosing compliance assessment. The identity of the study medications will be masked to the Investigator and study personnel responsible for study endpoint-related procedures. IOP measurements will be performed by the Investigator/designee who will be masked to the readout of the tonometer, which will be read and entered into the source documentation (whether electronic or paper) by a second staff member once the Investigator/designee reaches the correct applanation effect in the slit lamp.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nebivolol Ophthalmic Suspension 1 Percent
Administered twice daily to both eyes for 84 days (12 weeks)
Group Type
EXPERIMENTAL
Nebivolol Ophthalmic Suspension 1 Percent
Intervention Type
DRUG
1 drop instilled into each eye twice daily
Nebivolol Ophthalmic Suspension 0.5 Percent
Administered twice daily to both eyes for 84 days (12 weeks)
Group Type
EXPERIMENTAL
Nebivolol Ophthalmic Suspension 0.5 Percent
Intervention Type
DRUG
1 drop instilled into each eye twice daily
Timolol Ophthalmic Suspension 0.5 Percent
Administered twice daily to both eyes for 84 days (12 weeks)
Group Type
EXPERIMENTAL
Timolol Ophthalmic Suspension 0.5 Percent
Intervention Type
DRUG
1 drop instilled into each eye twice daily
Timolol Ophthalmic Solution 0.5 Percent
Administered twice daily to both eyes for 84 days (12 weeks)
Group Type
ACTIVE_COMPARATOR
Timolol Ophthalmic Solution 0.5 Percent
Intervention Type
DRUG
1 drop instilled into each eye twice daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nebivolol Ophthalmic Suspension 1 Percent
1 drop instilled into each eye twice daily
Intervention Type
DRUG
Nebivolol Ophthalmic Suspension 0.5 Percent
1 drop instilled into each eye twice daily
Intervention Type
DRUG
Timolol Ophthalmic Suspension 0.5 Percent
1 drop instilled into each eye twice daily
Intervention Type
DRUG
Timolol Ophthalmic Solution 0.5 Percent
1 drop instilled into each eye twice daily
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Willing and able to understand and sign an informed consent form prior to any study related procedures.
2. Able to administer or have a caregiver accurately administer an eye drop.
3. Have POAG or OHT in both eyes that requires therapy for IOP and is adequately controlled, in the opinion of the Investigator, on no more than 2 ocular hypotensive medications (fixed dose combinations count as 2 medications). Subjects with OHT on no ocular hypotensive medication are acceptable. Presence of POAG in one eye and OHT in the fellow eye is acceptable.
3\. Able, in the opinion of the Investigator, to safely discontinue use of ocular hypotensive medications, if applicable, and undergo the appropriate required washout period for ocular hypotensive medications prior to Visit 3/Qualification/Baseline.
4\. At Visit 3/Qualification/Baseline, at least one eye must have unmedicated (post washout) IOP ≥ 22 and ≤ 34 mm Hg at 8:00 AM and ≥ 18 and ≤ 34 mm Hg at 10:00 AM and 4:00 PM in the same eye(s) qualifying at the Visit 3 8:00 AM time point. The IOP must be at least 22 mm Hg at each consecutive measurement at the 8:00 AM time point.
5\. No significant VF (visual field) loss, defined as a mean deviation in either eye greater than - 12 dB or a central point of fixation \< 5 dB in either eye. If the VF performed at or within 90 days prior to Visit 1 does not meet study required parameters, it may be repeated (test should be prior to randomization at Visit 3/Qualification/Baseline).
6\. Best corrected visual acuity (BCVA) of +0.6 logMAR or better in both eyes at Visit 1/Screening and Visit 3/Qualification/Baseline.
7\. Central corneal thickness ≥ 480 and ≤ 600 μm in both eyes. Pachymetry within 90 days prior to Screening is acceptable.
8\. Shaffer gonioscopic grade ≥ 3 (in at least 3 quadrants) in both eyes. Gonioscopy within 90 days prior to randomization is acceptable.
9\. Female subjects must be 1-year postmenopausal, surgically sterilized (total hysterectomy, bilateral oophorectomy or bilateral tubal ligation \> 90 days prior to Visit 1/Screening), or women of childbearing potential with a negative urine pregnancy test at Visit 1/Screening and Visit 3/Qualification/Baseline who are not breastfeeding or planning a pregnancy during the study. Women of childbearing potential must use an acceptable form of contraception throughout the study. Acceptable methods include the use of at least one of the following:
* Intrauterine (IUD) device
* Hormonal contraceptive (oral, injection, patch, implant, ring); subjects must have been on the same hormonal contraceptive for ≥ 90 days prior to Visit 1/Screening
* Double barrier method (spermicide used with either a condom or diaphragm)
* Abstinence
2. Able to administer or have a caregiver accurately administer an eye drop.
3. Have POAG or OHT in both eyes that requires therapy for IOP and is adequately controlled, in the opinion of the Investigator, on no more than 2 ocular hypotensive medications (fixed dose combinations count as 2 medications). Subjects with OHT on no ocular hypotensive medication are acceptable. Presence of POAG in one eye and OHT in the fellow eye is acceptable.
3\. Able, in the opinion of the Investigator, to safely discontinue use of ocular hypotensive medications, if applicable, and undergo the appropriate required washout period for ocular hypotensive medications prior to Visit 3/Qualification/Baseline.
4\. At Visit 3/Qualification/Baseline, at least one eye must have unmedicated (post washout) IOP ≥ 22 and ≤ 34 mm Hg at 8:00 AM and ≥ 18 and ≤ 34 mm Hg at 10:00 AM and 4:00 PM in the same eye(s) qualifying at the Visit 3 8:00 AM time point. The IOP must be at least 22 mm Hg at each consecutive measurement at the 8:00 AM time point.
5\. No significant VF (visual field) loss, defined as a mean deviation in either eye greater than - 12 dB or a central point of fixation \< 5 dB in either eye. If the VF performed at or within 90 days prior to Visit 1 does not meet study required parameters, it may be repeated (test should be prior to randomization at Visit 3/Qualification/Baseline).
6\. Best corrected visual acuity (BCVA) of +0.6 logMAR or better in both eyes at Visit 1/Screening and Visit 3/Qualification/Baseline.
7\. Central corneal thickness ≥ 480 and ≤ 600 μm in both eyes. Pachymetry within 90 days prior to Screening is acceptable.
8\. Shaffer gonioscopic grade ≥ 3 (in at least 3 quadrants) in both eyes. Gonioscopy within 90 days prior to randomization is acceptable.
9\. Female subjects must be 1-year postmenopausal, surgically sterilized (total hysterectomy, bilateral oophorectomy or bilateral tubal ligation \> 90 days prior to Visit 1/Screening), or women of childbearing potential with a negative urine pregnancy test at Visit 1/Screening and Visit 3/Qualification/Baseline who are not breastfeeding or planning a pregnancy during the study. Women of childbearing potential must use an acceptable form of contraception throughout the study. Acceptable methods include the use of at least one of the following:
* Intrauterine (IUD) device
* Hormonal contraceptive (oral, injection, patch, implant, ring); subjects must have been on the same hormonal contraceptive for ≥ 90 days prior to Visit 1/Screening
* Double barrier method (spermicide used with either a condom or diaphragm)
* Abstinence
Exclusion Criteria
Ocular
1. Intraocular pressure ˃ 34 mm Hg in either eye at Visit 1/Screening, Visit 2/Washout Safety Check, or Visit 3/Qualification/Baseline.
2. Other forms of glaucoma in either eye, e.g., congenital glaucoma, closed-angle glaucoma, uveitic glaucoma, pseudoexfoliation or pigment dispersion syndrome, or history of angle closure. Narrow angles treated with peripheral iridotomy are allowed if at least 4 months status post iridotomy.
3. Current or recent (within 30 days prior to Visit 1/Screening) clinically significant ocular infection or inflammation, in the opinion of the Investigator, in either eye.
4. History of conjunctivitis within 90 days prior to Visit 1/Screening, or history of herpes simplex or herpes zoster in either eye.
5. Clinically significant ocular disease, in the opinion of the Investigator, in either eye (including, but not limited to corneal edema, uveitis, severe dry eye, proliferative diabetic retinopathy or macular degeneration) that might interfere with the study, confound study results, or put the subject at increased risk.
6. Have a cup-to disc (CD) ratio \> 0.8 at Visit 1/Screening in either eye.
7. Intravitreal steroid injections within 6 months prior to Visit 1/Screening. Subconjunctival or subtenon steroid injections within 90 days prior to Visit 1/Screening.
8. Use of topical ocular medications within 30 days prior to Visit 1/Screening other than ocular hypotensive medications and medications used as part of an eye examination. Artificial tears may be used during this period provided the use is not required for severe dry eye disease.
9. Clinically significant ocular trauma or incisional ocular surgery (including routine cataract surgery) in either eye within 6 months prior to Visit 1/Screening. Glaucoma filtering surgery, or minimally invasive glaucoma surgery within 12 months prior to Visit 1/Screening. Laser surgery for IOP reduction within 6 months prior to Visit 1/Screening. Non-incisional ocular surgery or non-glaucomatous laser treatment within 90 days prior to Visit 1/Screening.
10. Refractive surgery in either eye (i.e., radial keratotomy, photorefractive keratectomy \[PRK\], laser-assisted in situ keratomileusis \[LASIK\], corneal cross-linking, limbal relaxing incision) within 6 months prior to Visit 1/Screening.
11. Any ocular (e.g., corneal) abnormality preventing accurate assessment of IOP.
12. Contact lens wear within 1 week prior to Visit 1/Screening or unwillingness to discontinue wear of contacts lenses prior to and during the study period.
13. Aphakia.
General
14. Pregnancy or lactation.
15. Known hypersensitivity or contraindication to β-blockers (i.e., chronic obstructive pulmonary disease, bronchial asthma, unstable or abnormally low blood pressure or heart rate, second or third degree heart block or congestive heart failure, severe or unstable diabetes mellitus) that in the opinion of the Investigator may put the subject at risk from a topical ocular beta-blocker.
16. Have a condition or be in a situation which, in the Investigator's opinion, may put the subject at significant risk, confound study results, or interfere with the subject's participation in the study.
17. Clinically significant systemic disease (myasthenia gravis, hepatic, renal, endocrine, or cardiovascular disorders) that in the opinion of the Investigator might interfere with the study.
18. Use of systemic beta-adrenergic antagonists unless the dosage has been stable for 1 month prior to Visit 1/Screening and is expected to remain stable through the study period.
19. Use of systemic (oral, injectable, inhaled) or topical steroids within 30 days prior to Visit 1/Screening; topical dermatologic or intranasal steroids are acceptable provided the usage meets the criteria outlined in the Summary of Prohibited Medications and Procedures in the protocol.
20. Contraindication to the use of timolol, nebivolol, or any of the components of the investigational products.
21. Changes to systemic medication that could have an effect on IOP within 28 days prior to Visit 3/Qualification/Baseline.
22. Participation in any study of an investigational product within 30 days prior to Visit 1/Screening.
23. History of substance abuse within 1 year prior to Visit 1/Screening.
24. Screening and enrollment of employees or relatives of employees of the clinical site.
1. Intraocular pressure ˃ 34 mm Hg in either eye at Visit 1/Screening, Visit 2/Washout Safety Check, or Visit 3/Qualification/Baseline.
2. Other forms of glaucoma in either eye, e.g., congenital glaucoma, closed-angle glaucoma, uveitic glaucoma, pseudoexfoliation or pigment dispersion syndrome, or history of angle closure. Narrow angles treated with peripheral iridotomy are allowed if at least 4 months status post iridotomy.
3. Current or recent (within 30 days prior to Visit 1/Screening) clinically significant ocular infection or inflammation, in the opinion of the Investigator, in either eye.
4. History of conjunctivitis within 90 days prior to Visit 1/Screening, or history of herpes simplex or herpes zoster in either eye.
5. Clinically significant ocular disease, in the opinion of the Investigator, in either eye (including, but not limited to corneal edema, uveitis, severe dry eye, proliferative diabetic retinopathy or macular degeneration) that might interfere with the study, confound study results, or put the subject at increased risk.
6. Have a cup-to disc (CD) ratio \> 0.8 at Visit 1/Screening in either eye.
7. Intravitreal steroid injections within 6 months prior to Visit 1/Screening. Subconjunctival or subtenon steroid injections within 90 days prior to Visit 1/Screening.
8. Use of topical ocular medications within 30 days prior to Visit 1/Screening other than ocular hypotensive medications and medications used as part of an eye examination. Artificial tears may be used during this period provided the use is not required for severe dry eye disease.
9. Clinically significant ocular trauma or incisional ocular surgery (including routine cataract surgery) in either eye within 6 months prior to Visit 1/Screening. Glaucoma filtering surgery, or minimally invasive glaucoma surgery within 12 months prior to Visit 1/Screening. Laser surgery for IOP reduction within 6 months prior to Visit 1/Screening. Non-incisional ocular surgery or non-glaucomatous laser treatment within 90 days prior to Visit 1/Screening.
10. Refractive surgery in either eye (i.e., radial keratotomy, photorefractive keratectomy \[PRK\], laser-assisted in situ keratomileusis \[LASIK\], corneal cross-linking, limbal relaxing incision) within 6 months prior to Visit 1/Screening.
11. Any ocular (e.g., corneal) abnormality preventing accurate assessment of IOP.
12. Contact lens wear within 1 week prior to Visit 1/Screening or unwillingness to discontinue wear of contacts lenses prior to and during the study period.
13. Aphakia.
General
14. Pregnancy or lactation.
15. Known hypersensitivity or contraindication to β-blockers (i.e., chronic obstructive pulmonary disease, bronchial asthma, unstable or abnormally low blood pressure or heart rate, second or third degree heart block or congestive heart failure, severe or unstable diabetes mellitus) that in the opinion of the Investigator may put the subject at risk from a topical ocular beta-blocker.
16. Have a condition or be in a situation which, in the Investigator's opinion, may put the subject at significant risk, confound study results, or interfere with the subject's participation in the study.
17. Clinically significant systemic disease (myasthenia gravis, hepatic, renal, endocrine, or cardiovascular disorders) that in the opinion of the Investigator might interfere with the study.
18. Use of systemic beta-adrenergic antagonists unless the dosage has been stable for 1 month prior to Visit 1/Screening and is expected to remain stable through the study period.
19. Use of systemic (oral, injectable, inhaled) or topical steroids within 30 days prior to Visit 1/Screening; topical dermatologic or intranasal steroids are acceptable provided the usage meets the criteria outlined in the Summary of Prohibited Medications and Procedures in the protocol.
20. Contraindication to the use of timolol, nebivolol, or any of the components of the investigational products.
21. Changes to systemic medication that could have an effect on IOP within 28 days prior to Visit 3/Qualification/Baseline.
22. Participation in any study of an investigational product within 30 days prior to Visit 1/Screening.
23. History of substance abuse within 1 year prior to Visit 1/Screening.
24. Screening and enrollment of employees or relatives of employees of the clinical site.
Minimum Eligible Age
18 Years
Maximum Eligible Age
100 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Trial Runners, LLC
OTHER
Sponsor Role
collaborator
Summit Analytical LLC
INDUSTRY
Sponsor Role
collaborator
Betaliq, Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kristin Peterson
Role: STUDY_DIRECTOR
Trial Runners, LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site 0012
Newport Beach, California, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BTQ-1901-1902-201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension
NCT00804648
COMPLETED
PHASE4
Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
NCT01110499
COMPLETED
PHASE2
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
NCT07168902
RECRUITING
PHASE2
A Phase III Study of Travoprost/Timolol Combination in Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT00672997
COMPLETED
PHASE3
Safety and Efficacy of Travoprost/Timolol BAC-free
NCT00760539
COMPLETED
PHASE3
An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects
NCT00811564
COMPLETED
PHASE4
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
NCT00332384
COMPLETED
PHASE3
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
NCT00652106
COMPLETED
PHASE3
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
NCT01915940
COMPLETED
PHASE2
Safety and IOP-Lowering Effects of WB007
NCT04149899
COMPLETED
PHASE1/PHASE2
Travoprost 0.004%/Timolol 0.5% Versus Latanoprost 0.005%/Timolol in Chinese Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT00872651
COMPLETED
PHASE3
Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).
NCT04830397
COMPLETED
PHASE2
A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension
NCT02003534
COMPLETED
PHASE4
Intraocular Pressure Reduction With the Bimatoprost/Timolol Fixed Combination
NCT00941096
COMPLETED
PHASE4
A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension
NCT02742649
COMPLETED
PHASE1/PHASE2
Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma
NCT01446497
UNKNOWN
PHASE4
Study Evaluating the Safety and Intraocular Pressure (IOP) Lowering Response of Brimonidine Tartrate Ophthalmic Solution in Subjects With Open Angle Glaucoma or Ocular Hypertension
NCT01687426
COMPLETED
PHASE1
DE-111 Against Timolol Ophthalmic Solution 0.5%
NCT01342094
COMPLETED
PHASE3
Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension
NCT01157364
COMPLETED
PHASE1/PHASE2
Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension
NCT01310777
COMPLETED
PHASE3
Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension
NCT00822055
COMPLETED
PHASE4
Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension
NCT00822081
COMPLETED
PHASE4
Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance
NCT04412096
COMPLETED
PHASE4
Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension
NCT00763061
COMPLETED
PHASE4